

ACTIVE SURVEILLANCE

Herlemann, A., Huang, H. C., Alam, R., Tosoian, J., Kim, H. L., Klein, E. A., ... Cooperberg, M. R. (2019). Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. *Prostate Cancer Prostatic Dis.* <https://doi.org/10.1038/s41391-019-0167-9>

Hu, J. C., Tosoian, J. J., Qi, J., Kaye, D., Johnson, A., Linsell, S., ... Morngan, T. M. (2018). Clinical Utility of Gene Expression Classifiers in Men With Newly Diagnosed Prostate Cancer. *JCO Precis Oncol.* <https://doi.org/10.1200/po.18.00163>

Kim, H. L., Ping, L., Huang, H. C., Deheshi, S., Marti, T., Knudsen, B., ... Bismar, T. A. (2018). Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance. *Prostate Cancer and Prostatic Dis.* <https://doi.org/10.1038/s41391-018-0101-6>

Klein, E. A., Santiago-Jiménez, M., Yousefi, K., Robbins, B. A., Schaeffer, E. M., Trock, B. J., ... Ross, A. E. (2017). Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential. *J Urol.* <https://doi.org/10.1016/j.juro.2016.08.091>

DEFINITIVE THERAPY

Martin, D. T., Ghabili, K., Levi, A., Humphrey, P. A., & Sprenkle, P. C. (2019). Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies. *Urology.* <https://doi.org/10.1016/j.urology.2018.12.001>

Muralidhar, V., Zhang, J., Wang, Q., Mahal, B. A., Butler, S. S., Spratt, D. E., ... Nguyen, P. L. (2019). Genomic validation of three-tiered clinical sub-classification of high-risk prostate cancer. *Int J Radiat Oncol Biol Phys.* <https://doi.org/10.1016/j.ijrobp.2019.06.2510>

Beksac, A. T., Cumarasamy, S., Falagario, U., Xu, P., Takhar, M., Alshalalfa, M., ... Tewari, A. (2018). Multiparametric Magnetic Resonance Imaging Features Identify Aggressive Prostate Cancer at the Phenotypic and Transcriptomic Level. *J Urol.* <https://doi.org/10.1016/j.juro.2018.06.041>

Berlin, A., Murgic, J., Hosni, A., Pintilie, M., Salcedo, A., Fraser, M., ... Chua, M. L. K. (2018). Genomic classifier for guiding treatment of intermediate-risk prostate cancers to dose-escalated image-guided radiotherapy without hormone therapy. *Int J Radiat Oncol Biol Phys.* <https://doi.org/10.1016/j.ijrobp.2018.08.030>

Radtke, J. P., Takhar, M., Bonekamp, D., Kesch, C., Erho, N., du Plessis, M., ... Hadaschik, B. A. (2018). Transcriptome Wide Analysis of Magnetic Resonance Imaging-targeted Biopsy and Matching Surgical Specimens from High-risk Prostate Cancer Patients Treated with Radical Prostatectomy: The Target Must Be Hit. *Eur Urol Focus.* <https://doi.org/10.1016/j.euf.2017.01.005>

Spratt, D. E., Zhang, J., Santiago-Jimenez, M., Dess, R. T., Davis, J. W., Den, R. B., ... Nguyen, P. L. (2018). Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer. *J Clin Oncol.* <https://doi.org/10.1200/JCO.2017.74.2940>



DEFINITIVE THERAPY CONT.

Tosco, L., Laenen, A., Gevaert, T., Salmon, I., Decaestecker, C., Davicioni, E., ... Joniau, S. (2018). Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial. *BMC Cancer*. <https://doi.org/10.1186/s12885-018-4275-z>

Xu, M. J., Kornberg, Z., Gadzinski, A. J., Diao, D., Cowan, J. E., Wua, S. Y., ... Feng, F. Y. (2018). Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer. *Eur Urol Oncol*. <https://doi.org/doi.org/10.1016/j.euo.2018.11.002>

Nguyen, P. L., Deheshi, S., Davicioni, E., Buerki, C., Lotan, T. L., Chelliserry, J., ... Pollack, A. (2017). Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. *Eur Urol*. <https://doi.org/10.1016/j.eururo.2017.05.009>

Nguyen, P. L., Martin, N. E., Choeurng, V., Palmer-Aronsten, B., Kolisnik, T., Beard, C. J., ... Feng, F. Y. (2017). Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer. *Prostate Cancer and Prostatic Dis*. <https://doi.org/10.1038/pcan.2016.58>

Klein, E. A., Haddad, Z., Yousefi, K., Lam, L. L. C., Wang, Q., Choeurng, V., ... Magi-Galluzzi, C. (2016). Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk. *Urology*. <https://doi.org/10.1016/j.urology.2016.01.012>

Knudsen, B. S., Kim, H. L., Erho, N., Shin, H., Alshalalfa, M., Lam, L. L. C., ... Simko, J. P. (2016). Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens. *J Mol Diagn*. <https://doi.org/10.1016/j.jmoldx.2015.12.006>

Lee, H. J., Yousefi, K., Haddad, Z., Abdollah, F., Lam, L. L. C., Shin, H., ... Kane, C. J. (2016). Evaluation of a genomic classifier in radical prostatectomy patients with lymph node metastasis. *Res Rep Urol*. <https://doi.org/10.2147/RRU.S99997>

Stoyanova, R., Pollack, A., Takhar, M., Lynne, C., Parra, N., Lam, L. L. C., ... Ishkanian, A. (2016). Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies. *Oncotarget*. <https://doi.org/10.18632/oncotarget.10523>

EARLY THERAPY AFTER SURGERY

Marascio, J., Spratt, D. E., Zhang, J., Trabulsi, E. J., Le, T., Sedzorme, W. S., ... Den, R. B. (2019). Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy. *Prostate Cancer and Prostatic Dis.* <https://doi.org/10.1038/s41391-019-0185-7>

Van den Broeck, T., Moris, L., Gevaert, T., Tosco, L., Smeets, E., Fishbane, N., ... Joniau, S. (2019). Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery. *Eur Urol Oncol.* <https://doi.org/10.1016/j.euo.2018.12.007>

Karnes, R. J., Choeurng, V., Ross, A. E., Schaeffer, E. M., Klein, E. A., Freedland, S. J., ... Trock, B. J. (2018). Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. *Eur Urol.* <https://doi.org/10.1016/j.eururo.2017.03.036>

Dalela, D., Santiago-Jiménez, M., Yousefi, K., Karnes, R. J., Ross, A. E., Den, R. B., ... Abdollah, F. (2017). Genomic classifier augments the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer: Development and internal validation of a multivariable prognostic model. *J Clin Oncol.* <https://doi.org/10.1200/JCO.2016.69.9918>

Gore, J. L., du Plessis, M., Santiago-Jiménez, M., Yousefi, K., Thompson, D. J. S., Karsh, L., ... Lin, D. W. (2017). Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study. *Cancer.* <https://doi.org/10.1002/cncr.30665>

Lobo, J. M., Trifiletti, D. M., Sturz, V. N., Dicker, A. P., Buerki, C., Davicioni, E., ... Showalter, T. N. (2017). Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer. *Clin Genitourin Cancer.* <https://doi.org/10.1016/j.clgc.2016.08.012>

Spratt, D. E., Yousefi, K., Deheshi, S., Ross, A. E., Den, R. B., Schaeffer, E. M., ... Feng, F. Y. (2017). Individual patient-level meta-Analysis of the performance of the decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease. *J Clin Oncol.* <https://doi.org/10.1200/JCO.2016.70.2811>

Den, R. B., Santiago-Jimenez, M., Alter, J., Schliekelman, M., Wagner, J. R., Renzulli, J. F., ... Shah, N. L. (2016). Decipher correlation patterns post prostatectomy: Initial experience from 2 342 prospective patients. *Prostate Cancer and Prostatic Dis.* <https://doi.org/10.1038/pcan.2016.38>

Ross, A. E., Johnson, M. H., Yousefi, K., Davicioni, E., Netto, G. J., Marchionni, L., ... Schaeffer, E. M. (2016). Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. *Eur Urol.* <https://doi.org/10.1016/j.eururo.2015.05.042>

Badani, K. K., Thompson, D. J., Brown, G., Holmes, D., Kella, N., Albala, D., ... Hornberger, J. (2015). Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery. *BJU Int.* <https://doi.org/10.1111/bju.12789>

EARLY THERAPY AFTER SURGERY CONT.

Cooperberg, M. R., Davicioni, E., Crisan, A., Jenkins, R. B., Ghadessi, M., & Karnes, R. J. (2015). Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. *Eur Urol*. <https://doi.org/10.1016/j.eururo.2014.05.039>

Den, R. B., Yousefi, K., Trabulsi, E. J., Abdollah, F., Choeurng, V., Feng, F. Y., ... Karnes, R. J. (2015). Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. *J Clin Oncol*. <https://doi.org/10.1200/JCO.2014.59.0026>

Klein, E. A., Yousefi, K., Haddad, Z., Choeurng, V., Buerki, C., Stephenson, A. J., ... Davicioni, E. (2015). A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. *Eur Urol*. <https://doi.org/10.1016/j.eururo.2014.10.036>

Lobo, J. M., Dicker, A. P., Buerki, C., Daviconi, E., Karnes, R. J., Jenkins, R. B., ... Showalter, T. N. (2015). Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis. *PLoS ONE*. <https://doi.org/10.1371/journal.pone.0116866>

Nguyen, P. L., Shin, H., Yousefi, K., Thompson, D. J., Hornberger, J., Hyatt, A. S., ... Feng, F. Y. (2015). Impact of a Genomic Classifier of Metastatic Risk on Postprostatectomy Treatment Recommendations by Radiation Oncologists and Urologists. *Urology*. <https://doi.org/10.1016/j.urology.2015.04.004>

Michalopoulos, S. N., Kella, N., Payne, R., Yohannes, P., Singh, A., Hettinger, C., ... Hornberger, J. (2014). Influence of a genomic classifier on post-operative treatment decisions in high-risk prostate cancer patients: results from the PRO-ACT study. *Curr Med Res Opin*. <https://doi.org/10.1185/03007995.2014.919908>

Badani, K., Thompson, D. J. S., Buerki, C., Davicioni, E., Garrison, J., Ghadessi, M., ... Hornberger, J. (2013). Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group. *Oncotarget*. <https://doi.org/10.18632/oncotarget.918>

Erho, N., Crisan, A., Vergara, I. A., Mitra, A. P., Ghadessi, M., Buerki, C., ... Jenkins, R. B. (2013). Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy. *PLoS ONE*. <https://doi.org/10.1371/journal.pone.0066855>

Karnes, J. R., Bergstralh, E. J., Davicioni, E., Ghadessi, M., Buerki, C., Mitra, A. P., ... Jenkins, R. B. (2013). Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk Patient population. *J Urol*. <https://doi.org/10.1016/j.juro.2013.06.017>

SALVAGE THERAPY

- Spratt, D. E., Dai, D. L. Y., Den, R. B., Troncoso, P., Yousefi, K., Ross, A. E., ... Davis, J. W. (2018). Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. *Eur Urol*. <https://doi.org/10.1016/j.eururo.2017.11.024>
- Freedland, S. J., Choeurng, V., Howard, L., De Hoedt, A., du Plessis, M., Yousefi, K., ... Den, R. B. (2016). Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. *Eur Urol*. <https://doi.org/10.1016/j.eururo.2016.01.008>
- Glass, A. G., Leo, M. C., Haddad, Z., Yousefi, K., Du Plessis, M., Chen, C., ... Weinmann, S. (2016). Validation of a Genomic Classifier for Predicting Post-Prostatectomy Recurrence in a Community Based Health Care Setting. *J Urol*. <https://doi.org/10.1016/j.juro.2015.11.044>
- Ross, A. E., Den, R. B., Yousefi, K., Trock, B. J., Tosoian, J., Davicioni, E., ... Schaeffer, E. M. (2016). Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk. *Prostate Cancer and Prostatic Dis*. <https://doi.org/10.1038/pcan.2016.15>
- Ross, A. E., Feng, F. Y., Ghadessi, M., Erho, N., Crisan, A., Buerki, C., ... Schaeffer, E. M. (2014). A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. *Prostate Cancer and Prostatic Dis*. <https://doi.org/10.1038/pcan.2013.49>

GRID

Adams, E.J., Karthaus, W. R., Hoover, E., Liu, D., Gruet, A., Zhang, Z., ... Sawyers, C.L. (2019). FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. *Nature*. <https://doi.org/10.1038/s41586-019-1318-9>

Echevarria, M. I., Awasthi, S., Cheng, C. H., Berglund, A. E., Rounbehler, R. J., Gerke, T., ... Yamoah, K. (2019). African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome. *J Urol*. <https://doi.org/10.1097/JU.000000000000193>

Spratt, D. E., Alshalalfa, M., Fishbane, N., Weiner, A. B., Mehra, R., Mahal, B. A., ... Schaeffer, E. M. (2019). Transcriptomic heterogeneity of androgen receptor (AR) activity defines a de novo low AR-active subclass in treatment naïve primary prostate cancer. *Clin Cancer Res*. <https://doi.org/10.1158/1078-0432.CCR-19-1587>

Zhao, S. G., Lehrer, J., Chang, S. L., Das, R., Erho, N., Liu, Y., ... Feng, F. Y. (2019). The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. *Clin Cancer Res*. <https://doi.org/10.1093/jnci/djy141>

Karnes, R. J., Sharma, V., Choeurng, V., Ashab, H. A., Erho, N., Alshalalfa, M., ... Schaeffer, E. M. (2018). Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. *Clin Cancer Res*. <https://doi.org/10.1158/1078-0432.CCR-17-2745>

Alshalalfa, M., Verhaegh, G. W., Gibb, E. A., Santiago-Jiménez, M., Erho, N., Jordan, J., ... Schalken, J. A. (2017). Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients. *Oncotarget*. <https://doi.org/10.18632/oncotarget.15133>

Benzon, B., Zhao, S. G., Haffner, M. C., Takhar, M., Erho, N., Yousefi, K., ... Ross, A. E. (2017). Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. *Prostate Cancer Prostatic Dis*. <https://doi.org/10.1038/pcan.2016.49>

Zhao, S. G., Chang, S. L., Erho, N., Yu, M., Lehrer, J., Alshalalfa, M., ... Feng, F. Y. (2017). Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. *JAMA Oncol*. <https://doi.org/10.1001/jamaoncol.2017.0751>

Zhao, S. G., Chang, S. L., Spratt, D. E., Erho, N., Yu, M., Ashab, H. A., ... Feng, F. Y. (2016). Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. *Lancet Oncol*. [https://doi.org/10.1016/S1470-2045\(16\)30491-0](https://doi.org/10.1016/S1470-2045(16)30491-0)

Tomlins, S. A., Alshalalfa, M., Davicioni, E., Erho, N., Yousefi, K., Zhao, S., ... Feng, F. Y. (2015). Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. *Eur Urol*. <https://doi.org/10.1016/j.eururo.2015.04.033>